Hims & Hers Health, Inc. (HIMS)
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $36.17, moving 5.51% from the previous trading session.
HIMS Breakout Signals Structural Business Transformation
The stock rebounded from below $14 after a regulatory shock and is now trading above $37 on a diversified growth narrative. Monthly weight-loss subscriber additions exceed one hundred thousand, transforming GLP-1 products into a powerful customer acquisition funnel. Peptides, AI healthcare systems, and international expansion create multi-layered optionality beyond traditional telehealth and pharmacy models.
Hims & Hers stock jumps as Canaccord lifts target price ahead of FDA review
Hims & Hers Health shares (HIMS) surged 9% on Wednesday after Canaccord Genuity raised its price target on the telehealth company, citing improving sales trends, momentum in its weight-loss business, and growing optimism around its peptide opportunity. Canaccord analyst Maria Ripps maintained a Buy rating on the stock while increasing her price target to $40 from $32, implying additional upside from current levels.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Health, Inc. (HIMS) Stock Falls Amid Market Uptick: What Investors Need to Know
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $33.39, indicating a -1.62% shift from the previous trading day.
Hims' obesity drug business may get boost as employers drop coverage
Telehealth provider Hims and Hers Health may get a boost next year from employers dropping coverage of weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo to rein in costs, investors and analysts say.
Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $32.96, moving 1.73% from the previous trading session.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers: The Bull Case Remains Strong
Hims & Hers remains attractive at $33, supported by renewed Novo Nordisk partnership and unique access to patient demand. Despite weak Q1 2026 results—4% revenue growth, declining margins, and a net loss—international expansion and diversified categories are strengthening the long-term outlook. Management targets $6.5B+ revenue and $1.3B+ adjusted EBITDA by 2030, with valuation justified if retention and cross-sell improve.
Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $31.89, moving +1.33% from the previous trading session.
Hims & Hers Enters A New Phase
The Novo Nordisk partnership transformed Hims & Hers Health, Inc. from a fringe obesity player into an official healthcare ecosystem participant. Short interest remains elevated near 30%-32% of the HIMS float, leaving roughly 63 million shares vulnerable to further covering. HIMS management targets at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030 through platform expansion.
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
Hims & Hers Health, Inc. (HIMS) closed at $27.71 in the latest trading session, marking a -4.38% move from the prior day.
